GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on June 16, 2022, serves as a transaction notification for GSK Plc. The filing discloses insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) that occurred on June 13, 2022, on the London Stock Exchange.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| 2022-06-13 | Ordinary Shares (25p each) | £17.4747 | 130 shares (aggregate) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of executive share purchases.
Key Facts for Investor Verification
- Transaction Type: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan.
- Participants: Transactions involved 10 individuals, including CEO Emma Walmsley, President of Vaccines and Global Health Richard Connor, and CEO of ViiV Healthcare Daria Waterhouse.
- Volume Details: Most executives acquired 14 shares (7 partnership shares and 7 matching shares). President of Global Affairs, Paul Thomson, acquired 16 shares (8 partnership and 8 matching).
- Market Data: All transactions were executed at a uniform price of £17.4747 per share on the London Stock Exchange.